A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Trial Profile

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Avelumab (Primary)
  • Indications Adrenocortical carcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms JAVELIN Solid Tumor
  • Sponsors EMD Serono
  • Most Recent Events

    • 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Sep 2017 Updated results of 6 months follow up analysis (Data cut off: Sep, 2016; n=249) from patients of the two cohorts with metastatic urothelial carcinoma treated with Avelumab, presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Updated results (data cut off Dec 31, 2016, n=50) presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top